Abstract

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive motor neuron dysfunction and loss. A portion of ALS cases are caused by mutation of the proteasome shuttle factor Ubiquilin 2 (UBQLN2), but the molecular pathway leading from UBQLN2 dysfunction to disease remains unclear. Here, we demonstrate that UBQLN2 regulates the domesticated gag-pol retrotransposon 'paternally expressed gene 10' (PEG10) in human cells and tissues. In cells, the PEG10 gag-pol protein cleaves itself in a mechanism reminiscent of retrotransposon self-processing to generate a liberated 'nucleocapsid' fragment, which uniquely localizes to the nucleus and changes the expression of genes involved in axon remodeling. In spinal cord tissue from ALS patients, PEG10 gag-pol is elevated compared to healthy controls. These findings implicate the retrotransposon-like activity of PEG10 as a contributing mechanism in ALS through regulation of gene expression, and restraint of PEG10 as a primary function of UBQLN2.

Data availability

Figure 6 - Source Data 1 contains the normalized counts from RNA-Seq data used to generate figures. Figure 8 - Source Data 1 contains the abundance counts from proteomics data used to generate figures. Sequencing data have been deposited in the Gene Expression Omnibus (GEO) at GSE227789. Proteomics data is available on PRIDE at PXD031964. Analysis code for microscopy quantitation can be obtained from https://github.com/jwtay1/PEG10-image-analysis/. All other data is available in the manuscript or source materials. Correspondence and material requests should be directed to A. M. Whiteley (alexandra.whiteley@colorado.edu).

The following data sets were generated

Article and author information

Author details

  1. Holly H Black

    Department of Biochemistry, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1383-136X
  2. Jessica L Hanson

    Institute for Behavioral Genetics, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  3. Julia E Roberts

    Department of Biochemistry, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  4. Shannon N Leslie

    Department of Biochemistry, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  5. Will Campodonico

    Department of Biochemistry, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9098-5266
  6. Christopher C Ebmeier

    Department of Biochemistry, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7940-6190
  7. G Aaron Holling

    Department of Biochemistry, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  8. Jian Wei Tay

    Biofrontiers Institute, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8634-5039
  9. Autumn M Matthews

    Department of Biochemistry, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  10. Elizabeth Ung

    Department of Biochemistry, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
  11. Cristina I Lau

    Department of Biochemistry, University of Colorado Boulder, Boulder, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0850-9963
  12. Alexandra Whiteley

    Department of Biochemistry, University of Colorado Boulder, Boulder, United States
    For correspondence
    alexandra.whiteley@colorado.edu
    Competing interests
    Alexandra Whiteley, The University of Colorado, Boulder, has a patent pending for the use of PEG10 inhibitors on which the author is an inventor..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4144-7605

Funding

National Institute of General Medical Sciences (T32GM142607)

  • Julia E Roberts
  • Autumn M Matthews

National Cancer Institute (T32CA174648)

  • G Aaron Holling

Biological Sciences Initiative

  • Elizabeth Ung
  • Cristina I Lau

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2023, Black et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,162
    views
  • 365
    downloads
  • 12
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Holly H Black
  2. Jessica L Hanson
  3. Julia E Roberts
  4. Shannon N Leslie
  5. Will Campodonico
  6. Christopher C Ebmeier
  7. G Aaron Holling
  8. Jian Wei Tay
  9. Autumn M Matthews
  10. Elizabeth Ung
  11. Cristina I Lau
  12. Alexandra Whiteley
(2023)
UBQLN2 restrains the domesticated retrotransposon PEG10 to maintain neuronal health in ALS
eLife 12:e79452.
https://doi.org/10.7554/eLife.79452

Share this article

https://doi.org/10.7554/eLife.79452

Further reading

    1. Cell Biology
    2. Developmental Biology
    Evgenia Leikina, Jarred M Whitlock ... Leonid Chernomordik
    Research Article

    The bone-resorbing activity of osteoclasts plays a critical role in the life-long remodeling of our bones that is perturbed in many bone loss diseases. Multinucleated osteoclasts are formed by the fusion of precursor cells, and larger cells – generated by an increased number of cell fusion events – have higher resorptive activity. We find that osteoclast fusion and bone resorption are promoted by reactive oxygen species (ROS) signaling and by an unconventional low molecular weight species of La protein, located at the osteoclast surface. Here, we develop the hypothesis that La’s unique regulatory role in osteoclast multinucleation and function is controlled by an ROS switch in La trafficking. Using antibodies that recognize reduced or oxidized species of La, we find that differentiating osteoclasts enrich an oxidized species of La at the cell surface, which is distinct from the reduced La species conventionally localized within cell nuclei. ROS signaling triggers the shift from reduced to oxidized La species, its dephosphorylation and delivery to the surface of osteoclasts, where La promotes multinucleation and resorptive activity. Moreover, intracellular ROS signaling in differentiating osteoclasts oxidizes critical cysteine residues in the C-terminal half of La, producing this unconventional La species that promotes osteoclast fusion. Our findings suggest that redox signaling induces changes in the location and function of La and may represent a promising target for novel skeletal therapies.

    1. Cell Biology
    Xiaojiao Hua, Chen Zhao ... Yan Zhou
    Research Article

    The β-catenin-dependent canonical Wnt signaling is pivotal in organ development, tissue homeostasis, and cancer. Here, we identified an upstream enhancer of Ctnnb1 – the coding gene for β-catenin, named ieCtnnb1 (intestinal enhancer of Ctnnb1), which is crucial for intestinal homeostasis. ieCtnnb1 is predominantly active in the base of small intestinal crypts and throughout the epithelia of large intestine. Knockout of ieCtnnb1 led to a reduction in Ctnnb1 transcription, compromising the canonical Wnt signaling in intestinal crypts. Single-cell sequencing revealed that ieCtnnb1 knockout altered epithelial compositions and potentially compromised functions of small intestinal crypts. While deletion of ieCtnnb1 hampered epithelial turnovers in physiologic conditions, it prevented occurrence and progression of Wnt/β-catenin-driven colorectal cancers. Human ieCTNNB1 drove reporter gene expression in a pattern highly similar to mouse ieCtnnb1. ieCTNNB1 contains a single-nucleotide polymorphism associated with CTNNB1 expression levels in human gastrointestinal epithelia. The enhancer activity of ieCTNNB1 in colorectal cancer tissues was stronger than that in adjacent normal tissues. HNF4α and phosphorylated CREB1 were identified as key trans-factors binding to ieCTNNB1 and regulating CTNNB1 transcription. Together, these findings unveil an enhancer-dependent mechanism controlling the dosage of Wnt signaling and homeostasis in intestinal epithelia.